-
Peaceful Repeat Vote in Douglas Ward 3 Amid Heightened Security
-
‘They want silence’: how the film NAZA is shaking Israel
-
Belgian Ambassador Marks King’s Day in Athens Amidst Strong Bilateral Trade Ties
-
Dún Laoghaire-Rathdown €335m Budget Faces Mixed Reaction Over Housing and Cost of Living
-
Rediff.com IPO Risks: Gmail Dominance and New Business Ventures
-
BING X: 22,624.66 SNC have disappeared at BingX – how safe are tokens on BingX? Will BingX’s MiCAR licence be suspended?
-
Dubai Police Expand Luxury Patrol Fleet with 525-hp Defender
-
Iran Strikes US Sites in Kuwait Following US Airstrikes on Qeshm Island
-
ESGold Expands Montauban Gold-Silver Property to Approximately 26,787 Hectares Through Strategic Claim Staking
-
Investments & Wealth Institute Expands Advanced Education Offerings for 2027, Announces Next Experience Conference in Nashville
-
Wedgewood Weddings Acquires Swan Lake Overlook, Where Alpacas, Deer, and Mountain Views Join the Guest List
-
DSS Announces Completion of Impact Biomedical Business Combination with Zoar Limited
-
Newsmax Expands Over-the-Air Reach with HC2 Broadcasting Distribution Agreement for Newsmax2
-
Impala and Philanthropy Southwest Launch Southwest Hub, Mapping Philanthropy Across Eight States
-
HTB Activ(TM) Trial Demonstrates Significant Improvement in Cognitive Abilities
-
Nixxy Announces 1-for-20 Reverse Stock Split
-
IGC Pharma Completes Dosing in Phase 2 CALMA Trial of IGC-AD1 for Agitation in Alzheimer's Dementia
-
The IRS Watchdog Just Published Its FY 2027 Challenges List - Clear Start Tax Explains Why Agency Strain Rarely Slows Down Collection Notices
-
Who Does the Best Deep Plane Facelift in Oklahoma?
-
LHH ICEO Research Led by Harvard Business School Professor Maps Four Paths for Work Beyond the C-Suite
-
cbdMD Applauds Introduction of the Bipartisan Hemp Guardrails Act, Calling It a Win for Consumer Safety, American Jobs and Tax Revenue
-
Bell Rose Capital (OTCID:BELR) Makes Major Move Into Streaming Entertainment With Spark TV Partnership And New Billy Carson Series "The Missing Chapter"
-
Tocvan Defines Priority Gold Target Areas at Gran Pilar From Project-Wide Soil Sampling and Geologic Mapping; 225 Soils at or Above 100 ppb Gold
-
NuRAN Wireless Raises First Two Towers in Benin as 4G Rollout Beats Expectations in Cameroon and Ivory Coast
-
Rockhaven Announces Successful Completion of 2026 Klaza Bulk Sample Program
-
Silver Storm to Attend the 121 Mining Investment Conference in London, UK
-
American Resources Corporation Provides Strategic Business and Financial Reporting Update
-
Who Does the Best Deep Plane Facelift in Sarasota?
-
Jumia Reports Third Quarter 2026 Results
-
Ameriwest Advances Its Copper Focused Strategy Through Proposed Sale of Railroad Valley to Pure Energy Minerals
-
1933 Industries Completes LED Lighting Retrofit at Its 68,000 Sq. Ft. Cannabis Cultivation Facility in Las Vegas, Nevada - Ranks #3 in Cannabis Flower Sales
-
AbTherx Licenses Atlas(TM) Platform to Athenova Therapeutics for Next-Generation Targeted Alpha Radiopharmaceutical Discovery
-
DataMeds AI Subsidiary Helomics, Inc. Announces Cancer Target Discovery and Anticancer Peptides Drug Development Partnership With DiaGen AI, Inc.
-
What to Do When Two Households Become One
-
SmartBuyerAI Gives Car Buyers an Itemized Check of Dealer Offers as FTC Steps Up Price Transparency Enforcement
-
InterContinental Hotels Group PLC Announces Transaction in Own Shares - November 18
-
Fulcrum Metals PLC Announces Uranium Readings up to 0.42% U(3)O(8) at Charlot-Neely
-
Leggett Dynamics Wins 2026 Automotive News PACE Pilot Award For Smart Brushless Motor
-
Wyyerd Fiber Brings Arizona's Fastest Internet to the City of Phoenix
-
Digital Infrastructure World 2027 Announces First 85 Speakers as Registrants Represent 80GW of AI Buying Capacity
-
Bill Shelow, LIBRA Insurance Partners President and CEO, Receives NAILBA’s 2026 Douglas Mooers Award for Excellence
-
Oleria Extends Identity Governance to AI Agents, Tracing Every Agent Through the People and Credentials It Acts For
-
UCLA's Scooter Jackson named Week 11 Lott IMPACT Trophy Player of the Week
-
Paris Hilton Guides Loti as Chief Advocacy Officer to Put Digital Identity Protection in Everyone's Hands
-
Ondas and Aston Martin Aramco Formula One Team Launch Multi-Year Partnership Built for "Speed to Decision"
-
Who Does the Best Testosterone Replacement Therapy in Las Vegas?
-
CMP 2026-2027 Nonprofit Leadership Pulse Check
-
Nexteer's HMDD Wins Innovation Awards from PACE Pilot, CES and AutoTech Breakthrough
-
Coa Wealth Launches AI-Powered Software That Functions as a Private Investment Office for Individual Investors and Families
-
More Than Keyboards: Epomaker Brings Its Gaming World to G-STAR 2026
Scientists behind breakthrough cystic fibrosis treatment awarded top US prize
Cystic fibrosis was once a dire, likely deadly diagnosis, destroying a patient's ability to breathe and digest food -- but a revolutionary new treatment offers reason for hope.
And on Thursday the three scientists who developed the clinical advance were awarded America's most prestigious scientific award, taking home the Lasker prize.
The top honor is frequently cited as a pre-cursor for a potential Nobel, and this year it recognized the pulmonologist Michael Welsh along with researchers Jesus Gonzalez and Paul Negulescu from the US laboratory Vertex.
Their research has shed light on the causes of the disease and given rise to a new class of innovative drugs, including the flagship treatment Kaftrio -- known as Trikafta in the United States -- which are capable of stabilizing the otherwise debilitating condition.
"It's unbelievable. It's better than I ever hoped," Welsh told AFP. "You see these kids and they look healthy and they're not coughing. They're running around and playing."
"I almost can't believe it. Then they go, and they're getting married and they're having kids, and they're getting on with their lives."
That reality stands in sharp contrast to Welsh's memories from the early days of his career, when a cystic fibrosis diagnosis was a likely death sentence in childhood or adolescence.
The new award-winning treatment has been hailed as "revolutionary" by patient advocacy organizations.
It works by addressing the underlying causes of the inherited disease -- which wreaks havoc on the lungs and digestive system -- rather than its symptoms.
- 'Not totally broken' -
Some 100,000 people worldwide are estimated to suffer from cystic fibrosis, in which sticky mucus builds up in the lungs, digestive tract and other parts of the body.
After the 1989 discovery of the CFTR gene -- whose mutation was identified as the cause of the disease -- Welsh began dissecting the problem with fellow researchers.
"We thought, if we understand how CFTR works, we have a chance of fixing it," he said.
Gaining a better understanding of how the protein that the gene codes for led the pulmonologist down a path seeking how genetic mutations impaired its function.
Welsh identified two major anomalies caused by the most common mutation: a trapping of sorts of the protein within the cell, and its reduced performance.
The medical breakthrough resulted from experiments, notably some that showed how lowering temperature could help release the trapped protein.
"That meant it was not totally broken," Welsh remembered enthusiastically.
Armed with these discoveries, the American Cystic Fibrosis Foundation then approached researchers Gonzalez and Negulescu, who began studying the possibility of chemically reversing the identified malfunctions.
- 'Panning for gold' -
The notion of gene therapy -- which would aim to directly reverse the gene mutations -- had seemed on paper to be the simplest route.
But when it didn't work as hoped, patient organizations began to explore other options.
Gonzalez developed an innovative research technique using dyes that allowed for testing thousands of chemical compounds in record times.
"Without the screening, we would never have found these molecules," he said.
It was process akin to "panning for gold," recalled Negulescu.
But ultimately their dogged work paid off; they identified a handful of molecules that led to the birth of a new class of treatments.
Those molecules proved capable of restoring mobility to the stuck protein, and improving its function.
Kaftrio/Trikafta -- approved stateside in 2019 and classified by the World Health Organization as an essential treatment in 2025 -- is among them.
But their significant cost poses an obstacle for some patients, especially as the treatment is lifelong, and the therapy is ineffective in a small minority of patients including those with different mutations.
"The work is not done," said Negulescu.
P.Hernandez--AT